Drug intelligence / Profile preview

KL-AI20

Development stage: Preclinical
Lead developer: Kanglin Biotechnology
Modality: Gene Therapies

Overview

KL-AI20 is an investigational gene therapy candidate being developed by Kanglin Bio for the treatment of AIDS. Currently in the early research phase, the therapy is designed to utilize genetic modification to address the underlying pathology of HIV infection. While specific details regarding the molecular targets, genetic payload, and delivery vector (viral or non-viral) have not been publicly disclosed by the developer, the program is part of Kanglin Bio's pipeline focused on applying gene therapy platforms to chronic and genetic diseases.

Targets

Hb (Hemoglobin)

Beyond the preview

Go deeper on KL-AI20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KL-AI20.

Explore the full profile